

NFL BIOSCIENCES: LEADERSHIP TEAM PREPARING THE NEXT STAGES IN ITS DEVELOPMENT

The Chairman-Chief Executive Officer and the Managing Director are exchanging their roles within the governance structure to pave the way for Phase III and registration of its priority drug candidate for smoking cessation (NFL-101).

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, adopted a new governance organization following the meeting of its Board of Directors on October 17, 2024.

Bruno Lafont, Managing Director and co-founder, was appointed Chairman-Chief Executive Officer, with Ignacio Faus appointed as the Company’s Managing Director. This will ensure the best possible organization to address the new stages of development.

Bruno Lafont, co-founder, Director and previously Managing Director of NFL Biosciences, was appointed as its Chairman and Chief Executive Officer. He will be responsible for clinical and industrial development and structuring, particularly for NFL-101, the advanced drug candidate (Phase 2B completed) for smoking cessation. He is also one of the main shareholders of NFL Biosciences, holding nearly 9% of its capital to date.

Ignacio Faus, Director and previously Chairman and Chief Executive Officer of NFL Biosciences, has been appointed as its Managing Director. His mission is focused on financing the Company’s development and identifying licensing partners.

Bruno Lafont and Ignacio Faus add: *“With the results of the Phase 2B CESTO 2 study, we have demonstrated the strong potential of our drug candidate in the field of smoking cessation. We are now focusing our efforts on preparing for Phase III, both in terms of regulatory, industrial and clinical processes, and to secure the best sources and structures of financing. At this stage of the Company’s maturity, the swapping of our roles within the governance structure, made possible by our highly complementary areas of expertise, will enable NFL Biosciences to continue moving forward more efficiently with the development of NFL-101”.*

As of October 17, 2024, the Board of Directors of NFL Biosciences therefore comprises:

- Mr Bruno Lafont, Chairman of the Board of Directors, Chief Executive Officer
- Mr Ignacio Faus, Director, Managing Director
- Mr Francis Ahner, Independent Director
- Ms Dominique Côté, Independent Director
- Mr Yannick Plétan, Independent Director

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67

Agence Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68